Cost Effectiveness of Midostaurin in the Treatment of Newly Diagnosed FLT3-Mutated Acute Myeloid Leukemia in the United States View Full Text


Ontology type: schema:ScholarlyArticle     


Article Info

DATE

2019-02

AUTHORS

Eytan Stein, Jipan Xie, Emilie Duchesneau, Subrata Bhattacharyya, Umakanth Vudumula, Briana Ndife, Gaetano Bonifacio, Annie Guerin, Nanxin Li, George Joseph

ABSTRACT

OBJECTIVES: The aim of this study was to assess the cost effectiveness of midostaurin + cytarabine + daunorubicin (midostaurin arm) versus placebo + cytarabine + daunorubicin (placebo arm) in the treatment of adult patients with newly diagnosed FLT3-mutated acute myeloid leukemia (AML) who are eligible for standard cytarabine + daunorubicin chemotherapy, from a US third-party payer perspective. METHODS: A lifetime partitioned survival model with four health states (active disease, complete remission [CR], relapse, and death) was constructed. Efficacy inputs (time to CR or death, time to relapse or death, and overall survival) were estimated using data from the RATIFY trial (NCT00651261). Costs (inflated to 2016 US dollars) included treatment, drug monitoring, stem cell transplantation (SCT), adverse events costs, and medical costs associated with health states. Incremental costs per quality-adjusted life-year (QALY) and life-year (LY) gained were estimated. Deterministic (DSA) and probabilistic sensitivity analyses (and PSA) were performed to assess model robustness. RESULTS: In the base case, patients in the midostaurin arm incurred higher total direct costs over a lifetime compared with the placebo arm ($4,043,470 vs. $3,959,741), resulting in an incremental cost of $83,729; however, the midostaurin arm had better effectiveness, with 1.59 more LYs and 1.37 more QALYs. These led to a base-case incremental cost-effectiveness ratio (ICER) of $52,596 per LY, or $61,167 per QALY. Results were robust in the DSA. In the PSA, the probability of the midostaurin arm being cost-effective compared with the placebo arm was 65.9%, at a willingness to pay of $150,000/QALY. CONCLUSIONS: This analysis suggests that midostaurin is a cost-effective treatment for adult patients with newly diagnosed FLT3-mutated AML, from a US third-party payer perspective. More... »

PAGES

1-15

References to SciGraph publications

Identifiers

URI

http://scigraph.springernature.com/pub.10.1007/s40273-018-0732-4

DOI

http://dx.doi.org/10.1007/s40273-018-0732-4

DIMENSIONS

https://app.dimensions.ai/details/publication/pub.1107948331

PUBMED

https://www.ncbi.nlm.nih.gov/pubmed/30382485


Indexing Status Check whether this publication has been indexed by Scopus and Web Of Science using the SN Indexing Status Tool
Incoming Citations Browse incoming citations for this publication using opencitations.net

JSON-LD is the canonical representation for SciGraph data.

TIP: You can open this SciGraph record using an external JSON-LD service: JSON-LD Playground Google SDTT

[
  {
    "@context": "https://springernature.github.io/scigraph/jsonld/sgcontext.json", 
    "about": [
      {
        "id": "http://purl.org/au-research/vocabulary/anzsrc-for/2008/1402", 
        "inDefinedTermSet": "http://purl.org/au-research/vocabulary/anzsrc-for/2008/", 
        "name": "Applied Economics", 
        "type": "DefinedTerm"
      }, 
      {
        "id": "http://purl.org/au-research/vocabulary/anzsrc-for/2008/14", 
        "inDefinedTermSet": "http://purl.org/au-research/vocabulary/anzsrc-for/2008/", 
        "name": "Economics", 
        "type": "DefinedTerm"
      }
    ], 
    "author": [
      {
        "affiliation": {
          "alternateName": "Memorial Sloan Kettering Cancer Center", 
          "id": "https://www.grid.ac/institutes/grid.51462.34", 
          "name": [
            "Memorial Sloan Kettering Cancer Center, 1275 York Avenue, 10065, New York, NY, USA"
          ], 
          "type": "Organization"
        }, 
        "familyName": "Stein", 
        "givenName": "Eytan", 
        "id": "sg:person.01076061725.68", 
        "sameAs": [
          "https://app.dimensions.ai/discover/publication?and_facet_researcher=ur.01076061725.68"
        ], 
        "type": "Person"
      }, 
      {
        "affiliation": {
          "name": [
            "Analysis Group, Inc., 333 South Hope Street, 27th Floor, 90071, Los Angeles, CA, USA"
          ], 
          "type": "Organization"
        }, 
        "familyName": "Xie", 
        "givenName": "Jipan", 
        "id": "sg:person.01151424673.71", 
        "sameAs": [
          "https://app.dimensions.ai/discover/publication?and_facet_researcher=ur.01151424673.71"
        ], 
        "type": "Person"
      }, 
      {
        "affiliation": {
          "alternateName": "Analysis Group (United States)", 
          "id": "https://www.grid.ac/institutes/grid.417986.5", 
          "name": [
            "Analysis Group, Inc., 111 Huntington Avenue, 14th Floor, 02199, Boston, MA, USA"
          ], 
          "type": "Organization"
        }, 
        "familyName": "Duchesneau", 
        "givenName": "Emilie", 
        "id": "sg:person.015423623013.65", 
        "sameAs": [
          "https://app.dimensions.ai/discover/publication?and_facet_researcher=ur.015423623013.65"
        ], 
        "type": "Person"
      }, 
      {
        "affiliation": {
          "alternateName": "Novartis (India)", 
          "id": "https://www.grid.ac/institutes/grid.464975.d", 
          "name": [
            "Novartis Healthcare Private Limited, Hyderabad, India"
          ], 
          "type": "Organization"
        }, 
        "familyName": "Bhattacharyya", 
        "givenName": "Subrata", 
        "id": "sg:person.01261226053.01", 
        "sameAs": [
          "https://app.dimensions.ai/discover/publication?and_facet_researcher=ur.01261226053.01"
        ], 
        "type": "Person"
      }, 
      {
        "affiliation": {
          "alternateName": "Novartis (India)", 
          "id": "https://www.grid.ac/institutes/grid.464975.d", 
          "name": [
            "Novartis Healthcare Private Limited, Hyderabad, India"
          ], 
          "type": "Organization"
        }, 
        "familyName": "Vudumula", 
        "givenName": "Umakanth", 
        "id": "sg:person.015575127346.54", 
        "sameAs": [
          "https://app.dimensions.ai/discover/publication?and_facet_researcher=ur.015575127346.54"
        ], 
        "type": "Person"
      }, 
      {
        "affiliation": {
          "alternateName": "Novartis (United States)", 
          "id": "https://www.grid.ac/institutes/grid.418424.f", 
          "name": [
            "Novartis Pharmaceuticals Corporation, 1 Health Plaza, 07936, East Hanover, NJ, USA"
          ], 
          "type": "Organization"
        }, 
        "familyName": "Ndife", 
        "givenName": "Briana", 
        "id": "sg:person.014635142440.39", 
        "sameAs": [
          "https://app.dimensions.ai/discover/publication?and_facet_researcher=ur.014635142440.39"
        ], 
        "type": "Person"
      }, 
      {
        "affiliation": {
          "alternateName": "Novartis (United States)", 
          "id": "https://www.grid.ac/institutes/grid.418424.f", 
          "name": [
            "Novartis Pharmaceuticals Corporation, 1 Health Plaza, 07936, East Hanover, NJ, USA"
          ], 
          "type": "Organization"
        }, 
        "familyName": "Bonifacio", 
        "givenName": "Gaetano", 
        "id": "sg:person.011562221143.72", 
        "sameAs": [
          "https://app.dimensions.ai/discover/publication?and_facet_researcher=ur.011562221143.72"
        ], 
        "type": "Person"
      }, 
      {
        "affiliation": {
          "name": [
            "Analysis Group, Inc., 1000 de la Gaucheti\u00e8re Ouest, Bureau 1200, H3B4W5, Montr\u00e9al, QC, Canada"
          ], 
          "type": "Organization"
        }, 
        "familyName": "Guerin", 
        "givenName": "Annie", 
        "id": "sg:person.01036633021.78", 
        "sameAs": [
          "https://app.dimensions.ai/discover/publication?and_facet_researcher=ur.01036633021.78"
        ], 
        "type": "Person"
      }, 
      {
        "affiliation": {
          "alternateName": "Analysis Group (United States)", 
          "id": "https://www.grid.ac/institutes/grid.417986.5", 
          "name": [
            "Analysis Group, Inc., 111 Huntington Avenue, 14th Floor, 02199, Boston, MA, USA"
          ], 
          "type": "Organization"
        }, 
        "familyName": "Li", 
        "givenName": "Nanxin", 
        "id": "sg:person.01205312756.00", 
        "sameAs": [
          "https://app.dimensions.ai/discover/publication?and_facet_researcher=ur.01205312756.00"
        ], 
        "type": "Person"
      }, 
      {
        "affiliation": {
          "alternateName": "Novartis (United States)", 
          "id": "https://www.grid.ac/institutes/grid.418424.f", 
          "name": [
            "Novartis Pharmaceuticals Corporation, 1 Health Plaza, 07936, East Hanover, NJ, USA"
          ], 
          "type": "Organization"
        }, 
        "familyName": "Joseph", 
        "givenName": "George", 
        "id": "sg:person.01366702602.61", 
        "sameAs": [
          "https://app.dimensions.ai/discover/publication?and_facet_researcher=ur.01366702602.61"
        ], 
        "type": "Person"
      }
    ], 
    "citation": [
      {
        "id": "https://doi.org/10.2147/jbm.s100283", 
        "sameAs": [
          "https://app.dimensions.ai/details/publication/pub.1010653415"
        ], 
        "type": "CreativeWork"
      }, 
      {
        "id": "https://doi.org/10.1002/cncr.21847", 
        "sameAs": [
          "https://app.dimensions.ai/details/publication/pub.1013588363"
        ], 
        "type": "CreativeWork"
      }, 
      {
        "id": "https://doi.org/10.1002/cncr.21847", 
        "sameAs": [
          "https://app.dimensions.ai/details/publication/pub.1013588363"
        ], 
        "type": "CreativeWork"
      }, 
      {
        "id": "https://doi.org/10.1200/jco.2005.06.027", 
        "sameAs": [
          "https://app.dimensions.ai/details/publication/pub.1025429828"
        ], 
        "type": "CreativeWork"
      }, 
      {
        "id": "https://doi.org/10.1182/asheducation-2013.1.220", 
        "sameAs": [
          "https://app.dimensions.ai/details/publication/pub.1026922699"
        ], 
        "type": "CreativeWork"
      }, 
      {
        "id": "https://doi.org/10.1056/nejmoa1112304", 
        "sameAs": [
          "https://app.dimensions.ai/details/publication/pub.1028569182"
        ], 
        "type": "CreativeWork"
      }, 
      {
        "id": "https://doi.org/10.1182/blood-2002-05-1440", 
        "sameAs": [
          "https://app.dimensions.ai/details/publication/pub.1028925033"
        ], 
        "type": "CreativeWork"
      }, 
      {
        "id": "https://doi.org/10.4172/2329-6917.1000135", 
        "sameAs": [
          "https://app.dimensions.ai/details/publication/pub.1031953905"
        ], 
        "type": "CreativeWork"
      }, 
      {
        "id": "https://doi.org/10.1016/j.thorsurg.2014.12.003", 
        "sameAs": [
          "https://app.dimensions.ai/details/publication/pub.1032347522"
        ], 
        "type": "CreativeWork"
      }, 
      {
        "id": "sg:pub.10.1038/sj.leu.2401568", 
        "sameAs": [
          "https://app.dimensions.ai/details/publication/pub.1036106851", 
          "https://doi.org/10.1038/sj.leu.2401568"
        ], 
        "type": "CreativeWork"
      }, 
      {
        "id": "sg:pub.10.1038/sj.leu.2401568", 
        "sameAs": [
          "https://app.dimensions.ai/details/publication/pub.1036106851", 
          "https://doi.org/10.1038/sj.leu.2401568"
        ], 
        "type": "CreativeWork"
      }, 
      {
        "id": "https://doi.org/10.3109/10428191003661852", 
        "sameAs": [
          "https://app.dimensions.ai/details/publication/pub.1037868648"
        ], 
        "type": "CreativeWork"
      }, 
      {
        "id": "sg:pub.10.1038/bcj.2016.50", 
        "sameAs": [
          "https://app.dimensions.ai/details/publication/pub.1050065801", 
          "https://doi.org/10.1038/bcj.2016.50"
        ], 
        "type": "CreativeWork"
      }, 
      {
        "id": "sg:pub.10.1007/s40273-015-0327-2", 
        "sameAs": [
          "https://app.dimensions.ai/details/publication/pub.1051397787", 
          "https://doi.org/10.1007/s40273-015-0327-2"
        ], 
        "type": "CreativeWork"
      }, 
      {
        "id": "sg:pub.10.1007/s40273-015-0327-2", 
        "sameAs": [
          "https://app.dimensions.ai/details/publication/pub.1051397787", 
          "https://doi.org/10.1007/s40273-015-0327-2"
        ], 
        "type": "CreativeWork"
      }, 
      {
        "id": "https://doi.org/10.18553/jmcp.2014.20.11.1086", 
        "sameAs": [
          "https://app.dimensions.ai/details/publication/pub.1068661329"
        ], 
        "type": "CreativeWork"
      }, 
      {
        "id": "https://app.dimensions.ai/details/publication/pub.1078535182", 
        "type": "CreativeWork"
      }, 
      {
        "id": "https://doi.org/10.1182/asheducation-2012.1.43", 
        "sameAs": [
          "https://app.dimensions.ai/details/publication/pub.1078659884"
        ], 
        "type": "CreativeWork"
      }, 
      {
        "id": "https://app.dimensions.ai/details/publication/pub.1078999964", 
        "type": "CreativeWork"
      }, 
      {
        "id": "https://doi.org/10.1016/j.hoc.2017.03.002", 
        "sameAs": [
          "https://app.dimensions.ai/details/publication/pub.1085429978"
        ], 
        "type": "CreativeWork"
      }, 
      {
        "id": "https://doi.org/10.1182/blood-2017-05-782292", 
        "sameAs": [
          "https://app.dimensions.ai/details/publication/pub.1085618912"
        ], 
        "type": "CreativeWork"
      }, 
      {
        "id": "sg:pub.10.1007/s40265-017-0779-0", 
        "sameAs": [
          "https://app.dimensions.ai/details/publication/pub.1085990487", 
          "https://doi.org/10.1007/s40265-017-0779-0"
        ], 
        "type": "CreativeWork"
      }, 
      {
        "id": "sg:pub.10.1007/s40265-017-0779-0", 
        "sameAs": [
          "https://app.dimensions.ai/details/publication/pub.1085990487", 
          "https://doi.org/10.1007/s40265-017-0779-0"
        ], 
        "type": "CreativeWork"
      }, 
      {
        "id": "https://doi.org/10.1056/nejmoa1614359", 
        "sameAs": [
          "https://app.dimensions.ai/details/publication/pub.1086135118"
        ], 
        "type": "CreativeWork"
      }, 
      {
        "id": "https://doi.org/10.1080/13696998.2018.1425209", 
        "sameAs": [
          "https://app.dimensions.ai/details/publication/pub.1100213595"
        ], 
        "type": "CreativeWork"
      }, 
      {
        "id": "https://doi.org/10.2147/ceor.s153286", 
        "sameAs": [
          "https://app.dimensions.ai/details/publication/pub.1100618779"
        ], 
        "type": "CreativeWork"
      }, 
      {
        "id": "sg:pub.10.1007/s40273-018-0704-8", 
        "sameAs": [
          "https://app.dimensions.ai/details/publication/pub.1106288346", 
          "https://doi.org/10.1007/s40273-018-0704-8"
        ], 
        "type": "CreativeWork"
      }, 
      {
        "id": "sg:pub.10.1186/s12955-018-1013-9", 
        "sameAs": [
          "https://app.dimensions.ai/details/publication/pub.1107123531", 
          "https://doi.org/10.1186/s12955-018-1013-9"
        ], 
        "type": "CreativeWork"
      }
    ], 
    "datePublished": "2019-02", 
    "datePublishedReg": "2019-02-01", 
    "description": "OBJECTIVES: The aim of this study was to assess the cost effectiveness of midostaurin\u2009+\u2009cytarabine\u2009+\u2009daunorubicin (midostaurin arm) versus placebo\u2009+\u2009cytarabine\u2009+\u2009daunorubicin (placebo arm) in the treatment of adult patients with newly diagnosed FLT3-mutated acute myeloid leukemia (AML) who are eligible for standard cytarabine\u2009+\u2009daunorubicin chemotherapy, from a US third-party payer perspective.\nMETHODS: A lifetime partitioned survival model with four health states (active disease, complete remission [CR], relapse, and death) was constructed. Efficacy inputs (time to CR or death, time to relapse or death, and overall survival) were estimated using data from the RATIFY trial (NCT00651261). Costs (inflated to 2016 US dollars) included treatment, drug monitoring, stem cell transplantation (SCT), adverse events costs, and medical costs associated with health states. Incremental costs per quality-adjusted life-year (QALY) and life-year (LY) gained were estimated. Deterministic (DSA) and probabilistic sensitivity analyses (and PSA) were performed to assess model robustness.\nRESULTS: In the base case, patients in the midostaurin arm incurred higher total direct costs over a lifetime compared with the placebo arm ($4,043,470 vs. $3,959,741), resulting in an incremental cost of $83,729; however, the midostaurin arm had better effectiveness, with 1.59 more LYs and 1.37 more QALYs. These led to a base-case incremental cost-effectiveness ratio (ICER) of $52,596 per LY, or $61,167 per QALY. Results were robust in the DSA. In the PSA, the probability of the midostaurin arm being cost-effective compared with the placebo arm was 65.9%, at a willingness to pay of $150,000/QALY.\nCONCLUSIONS: This analysis suggests that midostaurin is a cost-effective treatment for adult patients with newly diagnosed FLT3-mutated AML, from a US third-party payer perspective.", 
    "genre": "research_article", 
    "id": "sg:pub.10.1007/s40273-018-0732-4", 
    "inLanguage": [
      "en"
    ], 
    "isAccessibleForFree": false, 
    "isPartOf": [
      {
        "id": "sg:journal.1102812", 
        "issn": [
          "1170-7690", 
          "1179-2027"
        ], 
        "name": "PharmacoEconomics", 
        "type": "Periodical"
      }
    ], 
    "name": "Cost Effectiveness of Midostaurin in the Treatment of Newly Diagnosed FLT3-Mutated Acute Myeloid Leukemia in the United States", 
    "pagination": "1-15", 
    "productId": [
      {
        "name": "readcube_id", 
        "type": "PropertyValue", 
        "value": [
          "7fe79dfb97d95648169577018d42954713cd0f6ebeaa6cfcf8dec4758abed0d0"
        ]
      }, 
      {
        "name": "pubmed_id", 
        "type": "PropertyValue", 
        "value": [
          "30382485"
        ]
      }, 
      {
        "name": "nlm_unique_id", 
        "type": "PropertyValue", 
        "value": [
          "9212404"
        ]
      }, 
      {
        "name": "doi", 
        "type": "PropertyValue", 
        "value": [
          "10.1007/s40273-018-0732-4"
        ]
      }, 
      {
        "name": "dimensions_id", 
        "type": "PropertyValue", 
        "value": [
          "pub.1107948331"
        ]
      }
    ], 
    "sameAs": [
      "https://doi.org/10.1007/s40273-018-0732-4", 
      "https://app.dimensions.ai/details/publication/pub.1107948331"
    ], 
    "sdDataset": "articles", 
    "sdDatePublished": "2019-04-11T02:25", 
    "sdLicense": "https://scigraph.springernature.com/explorer/license/", 
    "sdPublisher": {
      "name": "Springer Nature - SN SciGraph project", 
      "type": "Organization"
    }, 
    "sdSource": "s3://com-uberresearch-data-dimensions-target-20181106-alternative/cleanup/v134/2549eaecd7973599484d7c17b260dba0a4ecb94b/merge/v9/a6c9fde33151104705d4d7ff012ea9563521a3ce/jats-lookup/v90/0000000001_0000000264/records_8700_00000575.jsonl", 
    "type": "ScholarlyArticle", 
    "url": "https://link.springer.com/10.1007%2Fs40273-018-0732-4"
  }
]
 

Download the RDF metadata as:  json-ld nt turtle xml License info

HOW TO GET THIS DATA PROGRAMMATICALLY:

JSON-LD is a popular format for linked data which is fully compatible with JSON.

curl -H 'Accept: application/ld+json' 'https://scigraph.springernature.com/pub.10.1007/s40273-018-0732-4'

N-Triples is a line-based linked data format ideal for batch operations.

curl -H 'Accept: application/n-triples' 'https://scigraph.springernature.com/pub.10.1007/s40273-018-0732-4'

Turtle is a human-readable linked data format.

curl -H 'Accept: text/turtle' 'https://scigraph.springernature.com/pub.10.1007/s40273-018-0732-4'

RDF/XML is a standard XML format for linked data.

curl -H 'Accept: application/rdf+xml' 'https://scigraph.springernature.com/pub.10.1007/s40273-018-0732-4'


 

This table displays all metadata directly associated to this object as RDF triples.

215 TRIPLES      21 PREDICATES      51 URIs      19 LITERALS      7 BLANK NODES

Subject Predicate Object
1 sg:pub.10.1007/s40273-018-0732-4 schema:about anzsrc-for:14
2 anzsrc-for:1402
3 schema:author N8a5b260480b64234812cd071f977d986
4 schema:citation sg:pub.10.1007/s40265-017-0779-0
5 sg:pub.10.1007/s40273-015-0327-2
6 sg:pub.10.1007/s40273-018-0704-8
7 sg:pub.10.1038/bcj.2016.50
8 sg:pub.10.1038/sj.leu.2401568
9 sg:pub.10.1186/s12955-018-1013-9
10 https://app.dimensions.ai/details/publication/pub.1078535182
11 https://app.dimensions.ai/details/publication/pub.1078999964
12 https://doi.org/10.1002/cncr.21847
13 https://doi.org/10.1016/j.hoc.2017.03.002
14 https://doi.org/10.1016/j.thorsurg.2014.12.003
15 https://doi.org/10.1056/nejmoa1112304
16 https://doi.org/10.1056/nejmoa1614359
17 https://doi.org/10.1080/13696998.2018.1425209
18 https://doi.org/10.1182/asheducation-2012.1.43
19 https://doi.org/10.1182/asheducation-2013.1.220
20 https://doi.org/10.1182/blood-2002-05-1440
21 https://doi.org/10.1182/blood-2017-05-782292
22 https://doi.org/10.1200/jco.2005.06.027
23 https://doi.org/10.18553/jmcp.2014.20.11.1086
24 https://doi.org/10.2147/ceor.s153286
25 https://doi.org/10.2147/jbm.s100283
26 https://doi.org/10.3109/10428191003661852
27 https://doi.org/10.4172/2329-6917.1000135
28 schema:datePublished 2019-02
29 schema:datePublishedReg 2019-02-01
30 schema:description OBJECTIVES: The aim of this study was to assess the cost effectiveness of midostaurin + cytarabine + daunorubicin (midostaurin arm) versus placebo + cytarabine + daunorubicin (placebo arm) in the treatment of adult patients with newly diagnosed FLT3-mutated acute myeloid leukemia (AML) who are eligible for standard cytarabine + daunorubicin chemotherapy, from a US third-party payer perspective. METHODS: A lifetime partitioned survival model with four health states (active disease, complete remission [CR], relapse, and death) was constructed. Efficacy inputs (time to CR or death, time to relapse or death, and overall survival) were estimated using data from the RATIFY trial (NCT00651261). Costs (inflated to 2016 US dollars) included treatment, drug monitoring, stem cell transplantation (SCT), adverse events costs, and medical costs associated with health states. Incremental costs per quality-adjusted life-year (QALY) and life-year (LY) gained were estimated. Deterministic (DSA) and probabilistic sensitivity analyses (and PSA) were performed to assess model robustness. RESULTS: In the base case, patients in the midostaurin arm incurred higher total direct costs over a lifetime compared with the placebo arm ($4,043,470 vs. $3,959,741), resulting in an incremental cost of $83,729; however, the midostaurin arm had better effectiveness, with 1.59 more LYs and 1.37 more QALYs. These led to a base-case incremental cost-effectiveness ratio (ICER) of $52,596 per LY, or $61,167 per QALY. Results were robust in the DSA. In the PSA, the probability of the midostaurin arm being cost-effective compared with the placebo arm was 65.9%, at a willingness to pay of $150,000/QALY. CONCLUSIONS: This analysis suggests that midostaurin is a cost-effective treatment for adult patients with newly diagnosed FLT3-mutated AML, from a US third-party payer perspective.
31 schema:genre research_article
32 schema:inLanguage en
33 schema:isAccessibleForFree false
34 schema:isPartOf sg:journal.1102812
35 schema:name Cost Effectiveness of Midostaurin in the Treatment of Newly Diagnosed FLT3-Mutated Acute Myeloid Leukemia in the United States
36 schema:pagination 1-15
37 schema:productId N6eac977526494bc9a4d84b0116c3b012
38 Na09c2ff1d5ee4832abe91a17d945ca41
39 Naf8a38755ebb4a0aa6fd4786c28fe62e
40 Nb789d400d4f74a4da281eb97cdc37786
41 Nf7f821f3746540758d15e3456f8f5b87
42 schema:sameAs https://app.dimensions.ai/details/publication/pub.1107948331
43 https://doi.org/10.1007/s40273-018-0732-4
44 schema:sdDatePublished 2019-04-11T02:25
45 schema:sdLicense https://scigraph.springernature.com/explorer/license/
46 schema:sdPublisher Nb66f9727c5fe414ea4216ee12c062787
47 schema:url https://link.springer.com/10.1007%2Fs40273-018-0732-4
48 sgo:license sg:explorer/license/
49 sgo:sdDataset articles
50 rdf:type schema:ScholarlyArticle
51 N37f3352c397e4b8fa390561286ccfc3d rdf:first sg:person.01366702602.61
52 rdf:rest rdf:nil
53 N3f014dd1d22a4d6ca2dc319819191466 schema:name Analysis Group, Inc., 1000 de la Gauchetière Ouest, Bureau 1200, H3B4W5, Montréal, QC, Canada
54 rdf:type schema:Organization
55 N3fdb31e765fe4f4faea021aa28a4dcab rdf:first sg:person.015423623013.65
56 rdf:rest N718b226aa3e04b7a9958907f89eb9e31
57 N5a184e5e44c34a398f7fa1e393be5cc2 rdf:first sg:person.014635142440.39
58 rdf:rest N77502bf5b65341578067c796c3ba18ef
59 N6eac977526494bc9a4d84b0116c3b012 schema:name readcube_id
60 schema:value 7fe79dfb97d95648169577018d42954713cd0f6ebeaa6cfcf8dec4758abed0d0
61 rdf:type schema:PropertyValue
62 N718b226aa3e04b7a9958907f89eb9e31 rdf:first sg:person.01261226053.01
63 rdf:rest Ne7b94c2f354143469262b9421021f45d
64 N77502bf5b65341578067c796c3ba18ef rdf:first sg:person.011562221143.72
65 rdf:rest Nae564b6e19db4a848ce94f5a51f6e986
66 N8a5b260480b64234812cd071f977d986 rdf:first sg:person.01076061725.68
67 rdf:rest Nb5c6571b30bd4c7bb5db78b0524a1625
68 N8c5ea7ed7e5a41cb8e6d10a3b1edb509 rdf:first sg:person.01205312756.00
69 rdf:rest N37f3352c397e4b8fa390561286ccfc3d
70 Na09c2ff1d5ee4832abe91a17d945ca41 schema:name nlm_unique_id
71 schema:value 9212404
72 rdf:type schema:PropertyValue
73 Nae564b6e19db4a848ce94f5a51f6e986 rdf:first sg:person.01036633021.78
74 rdf:rest N8c5ea7ed7e5a41cb8e6d10a3b1edb509
75 Naf8a38755ebb4a0aa6fd4786c28fe62e schema:name doi
76 schema:value 10.1007/s40273-018-0732-4
77 rdf:type schema:PropertyValue
78 Nb5c6571b30bd4c7bb5db78b0524a1625 rdf:first sg:person.01151424673.71
79 rdf:rest N3fdb31e765fe4f4faea021aa28a4dcab
80 Nb66f9727c5fe414ea4216ee12c062787 schema:name Springer Nature - SN SciGraph project
81 rdf:type schema:Organization
82 Nb789d400d4f74a4da281eb97cdc37786 schema:name dimensions_id
83 schema:value pub.1107948331
84 rdf:type schema:PropertyValue
85 Nba6b9a2ede734e8fa1a24c18555c3647 schema:name Analysis Group, Inc., 333 South Hope Street, 27th Floor, 90071, Los Angeles, CA, USA
86 rdf:type schema:Organization
87 Ne7b94c2f354143469262b9421021f45d rdf:first sg:person.015575127346.54
88 rdf:rest N5a184e5e44c34a398f7fa1e393be5cc2
89 Nf7f821f3746540758d15e3456f8f5b87 schema:name pubmed_id
90 schema:value 30382485
91 rdf:type schema:PropertyValue
92 anzsrc-for:14 schema:inDefinedTermSet anzsrc-for:
93 schema:name Economics
94 rdf:type schema:DefinedTerm
95 anzsrc-for:1402 schema:inDefinedTermSet anzsrc-for:
96 schema:name Applied Economics
97 rdf:type schema:DefinedTerm
98 sg:journal.1102812 schema:issn 1170-7690
99 1179-2027
100 schema:name PharmacoEconomics
101 rdf:type schema:Periodical
102 sg:person.01036633021.78 schema:affiliation N3f014dd1d22a4d6ca2dc319819191466
103 schema:familyName Guerin
104 schema:givenName Annie
105 schema:sameAs https://app.dimensions.ai/discover/publication?and_facet_researcher=ur.01036633021.78
106 rdf:type schema:Person
107 sg:person.01076061725.68 schema:affiliation https://www.grid.ac/institutes/grid.51462.34
108 schema:familyName Stein
109 schema:givenName Eytan
110 schema:sameAs https://app.dimensions.ai/discover/publication?and_facet_researcher=ur.01076061725.68
111 rdf:type schema:Person
112 sg:person.01151424673.71 schema:affiliation Nba6b9a2ede734e8fa1a24c18555c3647
113 schema:familyName Xie
114 schema:givenName Jipan
115 schema:sameAs https://app.dimensions.ai/discover/publication?and_facet_researcher=ur.01151424673.71
116 rdf:type schema:Person
117 sg:person.011562221143.72 schema:affiliation https://www.grid.ac/institutes/grid.418424.f
118 schema:familyName Bonifacio
119 schema:givenName Gaetano
120 schema:sameAs https://app.dimensions.ai/discover/publication?and_facet_researcher=ur.011562221143.72
121 rdf:type schema:Person
122 sg:person.01205312756.00 schema:affiliation https://www.grid.ac/institutes/grid.417986.5
123 schema:familyName Li
124 schema:givenName Nanxin
125 schema:sameAs https://app.dimensions.ai/discover/publication?and_facet_researcher=ur.01205312756.00
126 rdf:type schema:Person
127 sg:person.01261226053.01 schema:affiliation https://www.grid.ac/institutes/grid.464975.d
128 schema:familyName Bhattacharyya
129 schema:givenName Subrata
130 schema:sameAs https://app.dimensions.ai/discover/publication?and_facet_researcher=ur.01261226053.01
131 rdf:type schema:Person
132 sg:person.01366702602.61 schema:affiliation https://www.grid.ac/institutes/grid.418424.f
133 schema:familyName Joseph
134 schema:givenName George
135 schema:sameAs https://app.dimensions.ai/discover/publication?and_facet_researcher=ur.01366702602.61
136 rdf:type schema:Person
137 sg:person.014635142440.39 schema:affiliation https://www.grid.ac/institutes/grid.418424.f
138 schema:familyName Ndife
139 schema:givenName Briana
140 schema:sameAs https://app.dimensions.ai/discover/publication?and_facet_researcher=ur.014635142440.39
141 rdf:type schema:Person
142 sg:person.015423623013.65 schema:affiliation https://www.grid.ac/institutes/grid.417986.5
143 schema:familyName Duchesneau
144 schema:givenName Emilie
145 schema:sameAs https://app.dimensions.ai/discover/publication?and_facet_researcher=ur.015423623013.65
146 rdf:type schema:Person
147 sg:person.015575127346.54 schema:affiliation https://www.grid.ac/institutes/grid.464975.d
148 schema:familyName Vudumula
149 schema:givenName Umakanth
150 schema:sameAs https://app.dimensions.ai/discover/publication?and_facet_researcher=ur.015575127346.54
151 rdf:type schema:Person
152 sg:pub.10.1007/s40265-017-0779-0 schema:sameAs https://app.dimensions.ai/details/publication/pub.1085990487
153 https://doi.org/10.1007/s40265-017-0779-0
154 rdf:type schema:CreativeWork
155 sg:pub.10.1007/s40273-015-0327-2 schema:sameAs https://app.dimensions.ai/details/publication/pub.1051397787
156 https://doi.org/10.1007/s40273-015-0327-2
157 rdf:type schema:CreativeWork
158 sg:pub.10.1007/s40273-018-0704-8 schema:sameAs https://app.dimensions.ai/details/publication/pub.1106288346
159 https://doi.org/10.1007/s40273-018-0704-8
160 rdf:type schema:CreativeWork
161 sg:pub.10.1038/bcj.2016.50 schema:sameAs https://app.dimensions.ai/details/publication/pub.1050065801
162 https://doi.org/10.1038/bcj.2016.50
163 rdf:type schema:CreativeWork
164 sg:pub.10.1038/sj.leu.2401568 schema:sameAs https://app.dimensions.ai/details/publication/pub.1036106851
165 https://doi.org/10.1038/sj.leu.2401568
166 rdf:type schema:CreativeWork
167 sg:pub.10.1186/s12955-018-1013-9 schema:sameAs https://app.dimensions.ai/details/publication/pub.1107123531
168 https://doi.org/10.1186/s12955-018-1013-9
169 rdf:type schema:CreativeWork
170 https://app.dimensions.ai/details/publication/pub.1078535182 schema:CreativeWork
171 https://app.dimensions.ai/details/publication/pub.1078999964 schema:CreativeWork
172 https://doi.org/10.1002/cncr.21847 schema:sameAs https://app.dimensions.ai/details/publication/pub.1013588363
173 rdf:type schema:CreativeWork
174 https://doi.org/10.1016/j.hoc.2017.03.002 schema:sameAs https://app.dimensions.ai/details/publication/pub.1085429978
175 rdf:type schema:CreativeWork
176 https://doi.org/10.1016/j.thorsurg.2014.12.003 schema:sameAs https://app.dimensions.ai/details/publication/pub.1032347522
177 rdf:type schema:CreativeWork
178 https://doi.org/10.1056/nejmoa1112304 schema:sameAs https://app.dimensions.ai/details/publication/pub.1028569182
179 rdf:type schema:CreativeWork
180 https://doi.org/10.1056/nejmoa1614359 schema:sameAs https://app.dimensions.ai/details/publication/pub.1086135118
181 rdf:type schema:CreativeWork
182 https://doi.org/10.1080/13696998.2018.1425209 schema:sameAs https://app.dimensions.ai/details/publication/pub.1100213595
183 rdf:type schema:CreativeWork
184 https://doi.org/10.1182/asheducation-2012.1.43 schema:sameAs https://app.dimensions.ai/details/publication/pub.1078659884
185 rdf:type schema:CreativeWork
186 https://doi.org/10.1182/asheducation-2013.1.220 schema:sameAs https://app.dimensions.ai/details/publication/pub.1026922699
187 rdf:type schema:CreativeWork
188 https://doi.org/10.1182/blood-2002-05-1440 schema:sameAs https://app.dimensions.ai/details/publication/pub.1028925033
189 rdf:type schema:CreativeWork
190 https://doi.org/10.1182/blood-2017-05-782292 schema:sameAs https://app.dimensions.ai/details/publication/pub.1085618912
191 rdf:type schema:CreativeWork
192 https://doi.org/10.1200/jco.2005.06.027 schema:sameAs https://app.dimensions.ai/details/publication/pub.1025429828
193 rdf:type schema:CreativeWork
194 https://doi.org/10.18553/jmcp.2014.20.11.1086 schema:sameAs https://app.dimensions.ai/details/publication/pub.1068661329
195 rdf:type schema:CreativeWork
196 https://doi.org/10.2147/ceor.s153286 schema:sameAs https://app.dimensions.ai/details/publication/pub.1100618779
197 rdf:type schema:CreativeWork
198 https://doi.org/10.2147/jbm.s100283 schema:sameAs https://app.dimensions.ai/details/publication/pub.1010653415
199 rdf:type schema:CreativeWork
200 https://doi.org/10.3109/10428191003661852 schema:sameAs https://app.dimensions.ai/details/publication/pub.1037868648
201 rdf:type schema:CreativeWork
202 https://doi.org/10.4172/2329-6917.1000135 schema:sameAs https://app.dimensions.ai/details/publication/pub.1031953905
203 rdf:type schema:CreativeWork
204 https://www.grid.ac/institutes/grid.417986.5 schema:alternateName Analysis Group (United States)
205 schema:name Analysis Group, Inc., 111 Huntington Avenue, 14th Floor, 02199, Boston, MA, USA
206 rdf:type schema:Organization
207 https://www.grid.ac/institutes/grid.418424.f schema:alternateName Novartis (United States)
208 schema:name Novartis Pharmaceuticals Corporation, 1 Health Plaza, 07936, East Hanover, NJ, USA
209 rdf:type schema:Organization
210 https://www.grid.ac/institutes/grid.464975.d schema:alternateName Novartis (India)
211 schema:name Novartis Healthcare Private Limited, Hyderabad, India
212 rdf:type schema:Organization
213 https://www.grid.ac/institutes/grid.51462.34 schema:alternateName Memorial Sloan Kettering Cancer Center
214 schema:name Memorial Sloan Kettering Cancer Center, 1275 York Avenue, 10065, New York, NY, USA
215 rdf:type schema:Organization
 




Preview window. Press ESC to close (or click here)


...